Variations in the mRNA expression of poly(ADP-ribose) polymerases, poly(ADP-ribose) glycohydrolase and ADP-ribosylhydrolase 3 in breast tumors and impact on clinical outcome

International Journal of Cancer

Volumn 133, Issue 12, 2013, Pages 2791-2800

  Bieche, Ivan ^a   Pennaneach, Vincent ^a,b   Driouch, Keltouma ^a   Vacher, Sophie ^a   Zaremba, Tomasz ^a,b   Susini, Aurélie ^a   Lidereau, Rosette ^a   Hall, Janet ^a,b,c  

^a INSTITUT CURIE   (France)

^b INSERM U612   (France)

^c ASTRAZENECA   (United Kingdom)

Author keywords

ARH3; breast cancer; PARG; PARP

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE DIPHOSPHATE RIBOSYLHYDROLASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE NUCLEOSIDASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER GRADING; CANCER RADIOTHERAPY; CONTROLLED STUDY; DNA REPAIR; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TUMOR BIOPSY; TUMOR INVASION; WESTERN BLOTTING;

ARH3; BREAST CANCER; PARG; PARP;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL CYCLE PROTEINS; FEMALE; GLYCOSIDE HYDROLASES; HUMANS; MIDDLE AGED; POLY(ADP-RIBOSE) POLYMERASES; RNA, MESSENGER;

EID: 84885604912     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28304     Document Type: Article

References (43)

1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
2. Durkacz BW, Omidiji O, Gray DA, et al. (ADP-ribose)n participates in DNA excision repair. Nature 1980; 283: 593-6.
3. De Vos M, Schreiber V, Dantzer F,. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol 2012; 84: 137-46.
4. Boehler C, Dantzer F,. PARP-3, a DNA-dependent PARP with emerging roles in double-strand break repair and mitotic progression. Cell Cycle 2011; 10: 1023-4.
5. Megnin-Chanet F, Bollet MA, Hall J,. Targeting poly(ADP-ribose) polymerase activity for cancer therapy. Cell Mol Life Sci 2010; 67: 3649-62.
6. Oka S, Kato J, Moss J,. Identification and characterization of a mammalian 39-kDa poly(ADP-ribose) glycohydrolase. J Biol Chem 2006; 281: 705-13.
7. Bloom HJ, Richardson WW,. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359-77.
8. Bieche I, Onody P, Laurendeau I, et al. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 1999; 45: 1148-56.
9. Bieche I, Parfait B, Laurendeau I, et al. Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer. Oncogene 2001; 20: 8109-15.
10. Bieche I, Parfait B, Le Doussal V, et al. Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy. Cancer Res 2001; 61: 1652-8.
11. Meier ELKAP,. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
12. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
13. Bieche I, Onody P, Tozlu S, et al. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 2003; 106: 758-65.
14. Godon C, Cordelieres FP, Biard D, et al. PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility. Nucleic Acids Res 2008; 36: 4454-64.
15. Chalmers A, Johnston P, Woodcock M, et al. PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation. Int J Radiat Oncol Biol Phys 2004; 58: 410-19.
16. Tan SH, Lee SC,. An update on chemotherapy and tumor gene expression profiles in breast cancer. Expert Opin Drug Metab Toxicol 2012; 8: 1083-113.
17. Bieche I, Tomasetto C, Regnier CH, et al. Two distinct amplified regions at 17q11-q21 involved in human primary breast cancer. Cancer Res 1996; 56: 3886-90.
18. Le Scodan R, Cizeron-Clairac G, Fourme E, et al. DNA repair gene expression and risk of locoregional relapse in breast cancer patients. Int J Radiat Oncol Biol Phys 2010; 78: 328-36.
19. Glenisson M, Vacher S, Callens C, et al. Identification of new candidate therapeutic target genes in triple-negative breast cancer. Genes Cancer 2012; 3: 63-70.
20. Ossovskaya V, Koo IC, Kaldjian EP, et al. Upregulation of poly (ADP-ribose) polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types. Genes Cancer 2010; 1: 812-21.
21. Goncalves A, Finetti P, Sabatier R, et al. Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Res Treat 2011; 127: 273-81.
22. Bieche I, de Murcia G, Lidereau R,. Poly(ADP-ribose) polymerase gene expression status and genomic instability in human breast cancer. Clin Cancer Res 1996; 2: 1163-7.
23. Negroni M, Bertazzoni U,. Differential expression and stability of poly(ADP-ribose)polymerase mRNA in human cells. Biochim Biophys Acta 1993; 1173: 133-40.
24. Carbone M, Rossi MN, Cavaldesi M, et al. Poly (ADP-ribosyl)ation is implicated in the G0-G1 transition of resting cells. Oncogene 2008; 27: 6083-92.
25. Wein KH, Netzker R, Brand K,. Cell cycle-related expression of poly(ADP-ribosyl)transferase in proliferating rat thymocytes. Biochim Biophys Acta 1993; 1176: 69-76.
26. Ghabreau L, Roux JP, Frappart PO, et al. Poly(ADP-ribose) polymerase-1, a novel partner of progesterone receptors in endometrial cancer and its precursors. Int J Cancer 2004; 109: 317-21.
27. Ghabreau L, Roux JP, Frappart PO, et al. Poly(ADP-ribose) polymerase-1, a novel partner of progesterone receptors in endometrial cancer and its precursors. Int J Cancer 2004; 109: 317-21.
28. Cavalieri E, Frenkel K, Liehr JG, et al. Estrogens as endogenous genotoxic agents-DNA adducts and mutations. J Natl Cancer Inst Monogr 2000; 27: 75-93.
29. Fischer WH, Keiwan A, Schmitt E, et al. Increased formation of micronuclei after hormonal stimulation of cell proliferation in human breast cancer cells. Mutagenesis 2001; 16: 209-12.
30. Zaremba T, Ketzer P, Cole M, et al. Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines. Br J Cancer 2009; 101: 256-62.
31. Zaremba T, Thomas HD, Cole M, et al. Poly (ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers. Biochem J 2011; 436: 671-9.
32. Wright RH, Castellano G, Bonet J, et al. CDK2-dependent activation of PARP-1 is required for hormonal gene regulation in breast cancer cells. Genes Dev 2012; 26: 1972-83.
33. Bolin C, Boudra MT, Fernet M, et al. The impact of cyclin-dependent kinase 5 depletion on poly(ADP-ribose) polymerase activity and responses to radiation. Cell Mol Life Sci 2012; 69: 951-62.
34. Boehler C, Gauthier LR, Mortusewicz O, et al. Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression. Proc Natl Acad Sci USA 2011; 108: 2783-8.
35. Rulten SL, Fisher AE, Robert I, et al. PARP-3 and APLF function together to accelerate nonhomologous end-joining. Mol Cell 2011; 41: 33-45.
36. Paddock MN, Bauman AT, Higdon R, et al. Competition between PARP-1 and Ku70 control the decision between high-fidelity and mutagenic DNA repair. DNA Repair 2011; 10: 338-43.
37. Meyer RG, Meyer-Ficca ML, Jacobson EL, et al. Human poly(ADP-ribose) glycohydrolase (PARG) gene and the common promoter sequence it shares with inner mitochondrial membrane translocase 23 (TIM23). Gene 2003; 314: 181-90.
38. Koh DW, Lawler AM, Poitras MF, et al. Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality. Proc Natl Acad Sci USA 2004; 101: 17699-704.
39. Min W, Cortes U, Herceg Z, et al. Deletion of the nuclear isoform of poly(ADP-ribose) glycohydrolase (PARG) reveals its function in DNA repair, genomic stability and tumorigenesis. Carcinogenesis 2010; 31: 2058-65.
40. Ame JC, Fouquerel E, Gauthier LR, et al. Radiation-induced mitotic catastrophe in PARG-deficient cells. J Cell Sci 2009; 122: 1990-2002.
41. Andrabi SA, Kim NS, Yu SW, et al. Poly(ADP-ribose) (PAR) polymer is a death signal. Proc Natl Acad Sci USA 2006; 103: 18308-13.
42. Blenn C, Wyrsch P, Bader J, et al. Poly(ADP-ribose)glycohydrolase is an upstream regulator of Ca2+ fluxes in oxidative cell death. Cell Mol Life Sci 2011; 68: 1455-66.
43. Le May N, Iltis I, Ame JC, et al. Poly (adp-ribose) glycohydrolase regulates retinoic acid receptor-mediated gene expression. Mol Cell 2012; 48: 785-98.